<?xml version="1.0"?>
<oembed><version>1.0</version><provider_name>Public Citizen</provider_name><provider_url>https://www.citizen.org</provider_url><author_name>Diane Krauthamer</author_name><author_url>https://www.citizen.org/author/dkrauthamer/</author_url><title>Comments to the EMA&#x2019;s Pharmacovigilance Risk Assessment Committee Regarding the Safety of Hydroxyethyl Starch Solutions - Public Citizen</title><type>rich</type><width>600</width><height>338</height><html>&lt;blockquote class="wp-embedded-content" data-secret="NxcG6FnffC"&gt;&lt;a href="https://www.citizen.org/article/comments-to-the-emas-pharmacovigilance-risk-assessment-committee-regarding-the-safety-of-hydroxyethyl-starch-solutions/"&gt;Comments to the EMA&#x2019;s Pharmacovigilance Risk Assessment Committee Regarding the Safety of Hydroxyethyl Starch Solutions&lt;/a&gt;&lt;/blockquote&gt;&lt;iframe sandbox="allow-scripts" security="restricted" src="https://www.citizen.org/article/comments-to-the-emas-pharmacovigilance-risk-assessment-committee-regarding-the-safety-of-hydroxyethyl-starch-solutions/embed/#?secret=NxcG6FnffC" width="600" height="338" title="&#x201C;Comments to the EMA&#x2019;s Pharmacovigilance Risk Assessment Committee Regarding the Safety of Hydroxyethyl Starch Solutions&#x201D; &#x2014; Public Citizen" data-secret="NxcG6FnffC" frameborder="0" marginwidth="0" marginheight="0" scrolling="no" class="wp-embedded-content"&gt;&lt;/iframe&gt;&lt;script type="text/javascript"&gt;
/* &lt;![CDATA[ */
/*! This file is auto-generated */
!function(d,l){"use strict";l.querySelector&amp;&amp;d.addEventListener&amp;&amp;"undefined"!=typeof URL&amp;&amp;(d.wp=d.wp||{},d.wp.receiveEmbedMessage||(d.wp.receiveEmbedMessage=function(e){var t=e.data;if((t||t.secret||t.message||t.value)&amp;&amp;!/[^a-zA-Z0-9]/.test(t.secret)){for(var s,r,n,a=l.querySelectorAll('iframe[data-secret="'+t.secret+'"]'),o=l.querySelectorAll('blockquote[data-secret="'+t.secret+'"]'),c=new RegExp("^https?:$","i"),i=0;i&lt;o.length;i++)o[i].style.display="none";for(i=0;i&lt;a.length;i++)s=a[i],e.source===s.contentWindow&amp;&amp;(s.removeAttribute("style"),"height"===t.message?(1e3&lt;(r=parseInt(t.value,10))?r=1e3:~~r&lt;200&amp;&amp;(r=200),s.height=r):"link"===t.message&amp;&amp;(r=new URL(s.getAttribute("src")),n=new URL(t.value),c.test(n.protocol))&amp;&amp;n.host===r.host&amp;&amp;l.activeElement===s&amp;&amp;(d.top.location.href=t.value))}},d.addEventListener("message",d.wp.receiveEmbedMessage,!1),l.addEventListener("DOMContentLoaded",function(){for(var e,t,s=l.querySelectorAll("iframe.wp-embedded-content"),r=0;r&lt;s.length;r++)(t=(e=s[r]).getAttribute("data-secret"))||(t=Math.random().toString(36).substring(2,12),e.src+="#?secret="+t,e.setAttribute("data-secret",t)),e.contentWindow.postMessage({message:"ready",secret:t},"*")},!1)))}(window,document);
/* ]]&gt; */
&lt;/script&gt;
</html><description>Public Citizen calls on the European Medicines Agency (EMA) Pharmacovigilance Risk Assessment Committee (PRAC) to follow the example of Sweden&#x2019;s Medical Products Agency and require the immediate removal of hydroxyethyl starch (HES) solutions from the market in Europe because the solutions cause kidney failure, bleeding, and death and there are safer alternatives available. Recent drug utilization studies in 10 European Union countries indicate the futility of the PRAC&#x2019;s 2013 decision to restrict the use of HES products in Europe.</description><thumbnail_url>https://www.citizen.org/wp-content/uploads/public_citizen_shared_link.jpg</thumbnail_url><thumbnail_width>1200</thumbnail_width><thumbnail_height>628</thumbnail_height></oembed>
